Overview

A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

Status:
Active, not recruiting

Trial end date:
2021-11-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Canagliflozin